Development of Isatin‐Based Schiff Bases Targeting VEGFR‐2 Inhibition: Synthesis, Characterization, Antiproliferative Properties, and QSAR Studies
作者:Israa A. Seliem、Siva S. Panda、Adel S. Girgis、Queen L. Tran、Mona F. Said、Mohamed S. Bekheit、Anwar Abdelnaser、Soad Nasr、Walid Fayad、Ahmed A. F. Soliman、Rajeev Sakhuja、Tarek S. Ibrahim、Zakaria K. M. Abdel‐Samii、Amany M. M. Al‐Mahmoudy
DOI:10.1002/cmdc.202200164
日期:2022.7.5
Development of anticancer drug candidates: Design and synthesis of isatin-based Schiffbases are reported. Some of the newly synthesized Schiffbases show potential anticancer activity against breast cancer cell lines with lower toxicity toward normal cells. Thus, these Schiffbases could lead to the development of potential drug candidates for breast cancer.
The ability of counterion enhanced catalysis to promote the asymmetric functionalization of enones was demonstrated. Combining the use of sterically demanding phosphoric acids with simple chiral diamines allowed for the preparation of simple ion-paired and highly tunable organocatalysts. The latter could be applied in four different asymmetric transformations, providing a highly enantioselective access
The inhibition of two human cytosolic carbonic anhydrase isozymes I and II, with some novel glycine and phenylalanine sulfonamide derivatives were investigated. Newly synthesized compounds G1-4 and P1-4 showed effective inhibition profiles with K-I values in the range of 14.66-315 mu M for hCA I and of 18.31-143.8 mu M against hCA II, respectively. In order to investigate the binding mechanisms of these inhibitors, in silico docking studies were applied. Atomistic molecular dynamic simulations were performed for docking poses which utilize to illustrate the inhibition mechanism of used inhibitors into active site of CAII. These sulfonamide containing compounds generally were competitive inhibitors with 4-nitro-phenylacetate as substrate. Some investigated compounds here showed effective hCA II inhibitory effects, in the same range as the clinically used sulfonamide, sulfanilamide or mafenide and might be used as leads for generating enzyme inhibitors possibly targeting other CA isoforms which have not been yet assayed for their interactions with such agents. (C) 2015 Elsevier Ltd. All rights reserved.